The Liver Meeting 2023-Hepotoxicity SIG - Drug Induced Liver Injury

Video Transcription

Video Summary

The video discusses managing immune-checkpoint inhibitor hepatitis by initiating corticosteroid therapy, escalating to higher doses for severe cases, and defining steroid-refractory disease based on biochemical response. It emphasizes involving hepatology specialists for confirmation of diagnosis, considering rechallenge with ICI therapy post-recovery, and evaluating the safety of rechallenge. Experts explore challenges in differentiating immune-related liver injury from other hepatotoxicity forms, discussing histological ambiguity and a two-hit model of injury. They highlight the need for further research on risk factors, management strategies, and biomarkers like bile acid profiles. The video also addresses challenges in managing steroid non-responders and tapering mycophenolate mofetil in combination therapy. More guidance and research are needed to enhance outcomes for patients with immune-related liver injury.

Keywords

immune-checkpoint inhibitor hepatitis

corticosteroid therapy

steroid-refractory disease

hepatology specialists

ICI therapy rechallenge

immune-related liver injury

hepatotoxicity forms

histological ambiguity

two-hit model of injury

risk factors

management strategies

bile acid profiles

mycophenolate mofetil

combination therapy